Hereditary Angioedema Therapeutic Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2034
Overview
Hereditary Angioedema Therapeutic Market size is projected to reach US$ 30.76 Bn at the end of the forecast period at a CAGR of 16.79%.
Increasing cases of hereditary angioedema (HAE) globally is a mainly driving the Hereditary Angioedema Therapeutic market. According to the National Organization for Rare Disorders (NORD), about 1-9 people per 100,000 population are affected by the condition. The actual number of individuals with the condition are significantly higher due to under-reporting and misdiagnosis. The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
Hereditary Angioedema Therapeutic Market Growth Outlook
To know about the Research Methodology :- Request Free Sample Report
In 2025, there were approximately 422,700 prevalent cases of hereditary angioedema worldwide, and forecasts that number to increase to xx K prevalent cases by 2034. This increasing cases of hereditary angioedema (HAE) is driving the hereditary angioedema (HAE) therapeutics market.
Lack of awareness about HAE International (HAE), an international hereditary angioedema patient organization, is a major reason for misdiagnosis, which in turn, leads to inadequate treatment being provided to patients.
The hereditary angioedema market is segmented into such as drug class, route of administration, by treatment type, and by region. By drug class market is further segmented into four other categories such as kallikrein inhibitor, selective bradykinin B2 receptor antagonist, C1 esterase inhibitor, and others. C1 esterase inhibitor segment is expected to exhibit highest market share at a CAGR of xx% over forecast period.
By geography, hereditary angioedema market is segmented into APAC, North America, Europe, MEA& Africa and Latin America. North America accounted for a leading share in the market in terms of revenue in 2025 owing to new product launches by major players, better reimbursement scenario, and a well-developed healthcare infrastructure. Growing patient awareness levels, coupled with launch of novel therapies for hereditary angioedema management, is expected to drive the market in the region.
Key players operating in hereditary angioedema market are BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, Shire Plc., Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., and KalVista Pharmaceuticals, Inc. These players are entering into distribution agreements in order to increase their market share boost and their presence across different geographies.
The objective of the report is to present comprehensive analysis of hereditary angioedema market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding hereditary angioedema market dynamics, structure by analysing the market segments, and project the global critical communication market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the hereditary angioedema market make the report investor’s guide.
Hereditary Angioedema Therapeutic Market Recent Development
| Date | Company | Development | Impact |
|---|---|---|---|
| 21 January 2026 | Ionis Pharmaceuticals & Otsuka Pharmaceutical | The European Commission granted marketing authorization for DAWNZERA (donidalorsen) as the first RNA-targeted therapy for HAE prevention. | Provides patients aged 12 and older with a novel subcutaneous prophylactic option to significantly reduce monthly attack rates. |
| 07 July 2025 | KalVista Pharmaceuticals | The FDA approved EKTERLY (sebetralstat) as the first and only oral on-demand treatment for acute HAE attacks. | Transforms disease management by enabling rapid, patient-friendly symptom relief without the need for intravenous or subcutaneous administration. |
| 20 August 2025 | Ionis Pharmaceuticals | The U.S. FDA officially authorized DAWNZERA (donidalorsen) for the prevention of recurrent HAE attacks. | Establishes a new regulatory standard for RNA-based therapies in the rare disease market. |
| 15 April 2025 | CSL Behring | The company expanded its clinical reach by advancing the commercial rollout of ANDEMBRY (garadacimab) as a targeted Factor XIIa inhibitor. | Strengthens the competitive landscape for long-term prophylaxis by utilizing a novel inhibition mechanism. |
Hereditary Angioedema Therapeutic Market Scope: Inquire before buying
| Global Hereditary Angioedema Therapeutic Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | US $ 7.61 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 16.79% | Market Size in 2034: | US $ 30.76 Bn. |
| Segments Covered: | by Drug Class | C1-esterase inhibitor Bradykinin B2 receptor antagonist Kallikrein inhibitor Others |
|
| by Treatment Type | Prophylaxis On-demand |
||
| by Route of Administration | Intravenous Subcutaneous Oral |
||
Hereditary Angioedema Therapeutic Market by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Hereditary Angioedema Therapeutic Market Key players
1.BioCryst Pharmaceuticals, Inc.
2.Ionis Pharmaceuticals, Inc.
3.Pharming Group N.V.
4.CSL Limited
5.Shire Plc
6.Attune Pharmaceuticals, Inc.
7.Adverum Biotechnologies, Inc.
8.KalVista Pharmaceuticals, Inc.
9.Novartis AG
10.CENTOGENE AG
11.Sanofi
12.Takeda Pharmaceutical Company Limited
13.Cipla
Frequently Asked Questions:
1. Which region has the largest share in Global Hereditary Angioedema Therapeutic Market?
Ans: North America region held the highest share in 2025.
2. What is the growth rate of Global Hereditary Angioedema Therapeutic Market?
Ans: The Global Hereditary Angioedema Therapeutic Market is growing at a CAGR of 16.79% during forecasting period 2026-2034.
3. What is scope of the Global Hereditary Angioedema Therapeutic market report?
Ans: Global Hereditary Angioedema Therapeutic Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Hereditary Angioedema Therapeutic market?
Ans: The important key players in the Global Hereditary Angioedema Therapeutic Market are – BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, Shire Plc, Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, Inc., Novartis AG, CENTOGENE AG, Sanofi, Takeda Pharmaceutical Company Limited, and Cipla
5. What is the study period of this market?
Ans: The Global Hereditary Angioedema Therapeutic Market is studied from 2020 to 2034.